alterity therapeutics limited researches and develops therapeutic drugs for the treatment of parkinsonian's disease and other neurodegenerative diseases in australia. the company's lead drug candidates is ath434 that has completed phase i clinical trial for the treatment of parkinson's disease. it is also developing pbt2 for used as an antimicrobial agent. the company was formerly known as prana biotechnology limited and changed its name to alterity therapeutics limited in april 2019. the company was founded in 1997 and is based in melbourne, australia.
Company profile
Ticker
ATHE, PRNAF
Exchange
Website
CEO
Geoffrey Kempler
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
PRANA BIOTECHNOLOGY LTD
SEC CIK
ATHE stock data
Latest filings (excl ownership)
6-K
Report of Foreign Private Issuer
16 Apr 24
6-K
Appendix 2A - Application for quotation of securities
15 Apr 24
6-K
Results of Extraordinary General Meeting
12 Apr 24
6-K
Report of Foreign Private Issuer
12 Apr 24
6-K
Alterity Therapeutics Receives a $3.9 million Research & Development Tax Incentive Refund
26 Mar 24
6-K
Report of Foreign Private Issuer
14 Mar 24
6-K
Report of Foreign Private Issuer
4 Mar 24
6-K
Appendix 2A - Application for quotation of securities
4 Mar 24
6-K
Results for announcement to the market
28 Feb 24
6-K
Report of Foreign Private Issuer
22 Feb 24
Latest ownership filings
SC 13D/A
Life Biosciences LLC
31 Oct 22
SC 13D/A
Life Biosciences LLC
26 Aug 22
SC 13D/A
Life Biosciences LLC
1 Aug 22
SC 13D/A
Life Biosciences LLC
21 Jul 22
SC 13D/A
Life Biosciences LLC
28 Mar 22
SC 13D/A
Life Biosciences LLC
4 Mar 22
SC 13D/A
Life Biosciences LLC
8 Jul 21
SC 13D/A
Life Biosciences LLC
25 Nov 20
SC 13D/A
Life Biosciences LLC
26 Oct 20
SC 13D/A
Life Biosciences LLC
6 Jul 20
Financial summary
Quarter (USD) | Jun 23 | Jun 22 | Jun 21 | Jun 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Jun 23 | Jun 22 | Jun 21 | Jun 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Institutional ownership, Q2 2022
13F holders | Current |
---|---|
Total holders | 1 |
Opened positions | 0 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 188.72 mm |
Total shares | 238.11 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Life Biosciences | 238.11 mm | $188.72 mm |
News
Alterity Therapeutics Parkinson's Disease and Multiple System Atrophy Data Featured at the American Academy of Neurology (AAN) 2024 Annual Meeting
17 Apr 24
12 Health Care Stocks Moving In Monday's After-Market Session
15 Apr 24
Why Ultragenyx Pharmaceutical Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Monday's Mid-Day Session
15 Apr 24
12 Health Care Stocks Moving In Monday's Intraday Session
15 Apr 24
12 Health Care Stocks Moving In Monday's Pre-Market Session
15 Apr 24
Press releases
Alterity Therapeutics Parkinson's Disease and Multiple System Atrophy Data Featured at the American Academy of Neurology (AAN) 2024 Annual Meeting
17 Apr 24
Alterity Therapeutics to Present New Data on ATH434 at the World Orphan Drug Congress USA 2024
10 Apr 24
Alterity Therapeutics Receives a A$3.9 Million Research & Development Tax Incentive Refund
26 Mar 24
Alterity Therapeutics to Present New Data at the Upcoming American Academy of Neurology 2024 Annual Meeting
20 Feb 24
Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned After Second Review
6 Feb 24